Bazill G W, Dexter T M
Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.
Cancer Res. 1990 Dec 1;50(23):7505-12.
We investigated the effect of a number of platelet activating factor antagonists on cell killing by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphoryl choline (ET-18-OCH3). Of six platelet activating factor antagonists tested, four were found to protect WEHI-3B leukemic cells against cell death induced by ET-18-OCH3. Certain other compounds, not platelet activating factor antagonists, had similar protective effects. The protective compounds were all lipophilic weak bases. We describe experiments that indicate that these compounds protect by inhibition of endocytic uptake of ET-18-OCH3. Sensitive cells showed rapid endocytic uptake, whereas in resistant cells, uptake was slow. Uptake of ET-18-OCH3 could be suppressed by inhibitors of endocytosis such as chloroquine, monensin, and vinblastine. We conclude that one of the principal determinants of sensitivity or resistance to ether lipids may be the rate at which cells take them up by endocytosis.
我们研究了多种血小板活化因子拮抗剂对1-O-十八烷基-2-O-甲基-sn-甘油-3-磷酸胆碱(ET-18-OCH3)诱导细胞杀伤的影响。在所测试的六种血小板活化因子拮抗剂中,发现有四种可保护WEHI-3B白血病细胞免受ET-18-OCH3诱导的细胞死亡。某些其他化合物,并非血小板活化因子拮抗剂,也具有类似的保护作用。这些具有保护作用的化合物均为亲脂性弱碱。我们描述的实验表明,这些化合物通过抑制ET-18-OCH3的内吞摄取发挥保护作用。敏感细胞表现出快速的内吞摄取,而耐药细胞的摄取则较慢。内吞抑制剂如氯喹、莫能菌素和长春碱可抑制ET-18-OCH3的摄取。我们得出结论,细胞对醚脂敏感性或耐药性的主要决定因素之一可能是细胞通过内吞作用摄取它们的速率。